All articles from EyeWorld.org on the topic of artificial intelligence. EyeWorld is the award-winning member publication of ASCRS. The magazine provides news and updates from the Society as well as clinical features in the areas of cataract, refractive, cornea, glaucoma, and practice management. It publishes quarterly with editorial direction from its medical editorial board and staff.
➤ Roll-out expanded for presbyopia-correcting IOL ➤ Study: Phase 3 clinical trials evaluate phentolamine ophthalmic solution ➤ AI listening innovation for ophthalmologists ➤ ASCRS news and events
➤ First patient enrolled in Phase 3 trial evaluating phentolamine ophthalmic solution ➤ FDA clears IND amendment for Phase 3 retinitis pigmentosa gene therapy study ➤ Successful pre-submission meetings held for bioengineered corneal implants ➤ Study: AI chatbots pass ophthalmology board certification questions ➤ ASCRS news and events
➤ Study: artificial intelligence matches/outperforms ophthalmologists ➤ Primary endpoint met in Phase 3 trial using an antibody to treat thyroid eye disease ➤ FDA grants Breakthrough Device Designation to novel spectacle design ➤ ASCRS news and events
This article focused on opportunities to leverage AI to streamline ophthalmology practices.
➤ FDA expands eye drop warning list ➤ Positive results in Phase 2a trial for new biodegradable sustained drug delivery implant ➤ Phase 2b study begins for investigational therapy for acute infectious conjunctivitis ➤ FDA approves additional treatment indication for bispecific antibody ➤ Enrollment complete for study evaluating femtosecond laser-created trabeculotomy ➤ Company to study personalized medicine for patients with wet AMD ➤ Enrollment complete for Phase 2b trial evaluating wet AMD therapy ➤ Pivotal trial for wet AMD therapy begins ➤ Survey evaluates female ophthalmologist experiences ➤ ASCRS news and events
➤ First AI foundation model in ophthalmology ➤ 24-month topline data from Phase 3 geographic atrophy therapy ➤ Positive data from Phase 1/2 trial for retinitis pigmentosa, Leber congenital amaurosis treatment ➤ FDA clearance granted for portable retinal imaging system ➤ ASCRS news and events
➤ Phase 2 trial with experimental geographic atrophy treatment shows preservation of visual function ➤ AI-enabled screening system receives FDA clearance ➤ Enrollment complete for study evaluating investigational first-line therapy for DME ➤ Updates from two retinitis pigmentosa trials ➤ ASCRS news and events
EyeWorld had a conversation with Eric Rosenberg, DO, and John Kitchens, MD, about the Digital Ophthalmic Society (DOS), which they co-founded and launched in April 2022. The discussion covered what DOS is and digital innovation in ophthalmology.
➤ FDA approves brolucizumab injection for DME ➤ NDA filed for geographic atrophy drug ➤ Study: Dietary supplements can slow AMD progression ➤ First global study evaluates AI for diabetic retinopathy and referral uptake ➤ Plans to begin two Phase 3 trials for investigational thyroid eye disease therapy ➤ ASCRS news and events
➤ Machine assesses cardiovascular risk with retinal scan ➤ FDA requests more info for BLA for bevacizumab ➤ Genetic variables affect NMOSD treatment ➤ Study: 12-month results from canaloplasty-trabeculotomy procedure ➤ Topline results from Phase 3 pivotal trial evaluating pupil-modulating drug ➤ ASCRS news and events
Get the latest ophthalmology news delivered to your inbox every Friday.